Its Phase News Today

Issuer: Immunic, Inc. / Key word(s): Study Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 17.08.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Completes Enrollment of Its P...

OMO-103 in Phase 1b clinical trial Peptomyc logo Peptomyc logo BARCELONA, Spain, July 27, 2023 (Newswire.com) - Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for can...

Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 ...

/PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd together with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd....

CHANGSHA, China, May 18, 2023 /PRNewswire/ -- On May 10th and 11th, SINOBOOM, a prominent manufacturer of MEWPs (Mobile Elevating Work Platforms) that specializes in researching, manufacturing

Issuer: Immunic, Inc. / Key word(s): Study results Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human

Issuer: Immunic, Inc. / Key word(s): Study Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease 05.05.2022 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic Announces Start of Patient Cohorts in Its Phase 1 Cli...

Issuer: Immunic, Inc. / Key word(s): Study Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease 05.05.2022 / 12:30 The issuer is

Analysts called these out as a group of emerging agents that could one day supplant our existing coronavirus therapies.

Battered by the second wave of covid-19, the government recalibrates its vaccination strategy in the hope of inoculating India's 900 million adult population by December 31. How realistic is this target? - Issue Date: Jun 21, 2021